Novel GPR52 agonist shows antipsychotic-like effects
AI Briefing
- • Researchers developed a novel GPR52 agonist, showing promising antipsychotic-like effects in preclinical trials.
- • GPR52 is predominantly expressed in the striatum, regulating dopaminergic and glutamatergic signaling pathways.
- • The agonist may provide a new therapeutic approach for treating psychiatric disorders.
Context
Researchers have found that a novel GPR52 agonist has antipsychotic-like effects. GPR52 is a receptor predominantly expressed in the striatum, a brain region involved in various functions. The striatum plays a role in cognition, motivation, and motor control.
GPR52 regulates signaling pathways implicated in psychiatric disorders, including dopaminergic and glutamatergic pathways.
Advertisement